Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Woo Jung Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9273-261X; OpenAlex author ID A5100712829. Sources: OpenAlex.

Their work

Papers
59 (first author 2, last author 21)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 6 papers · 2014: 5 papers · 2015: 2 papers · 2016: 6 papers · 2017: 5 papers · 2018: 2 papers · 2019: 4 papers · 2020: 12 papers · 2021: 5 papers · 2022: 6 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 50 of 59

  1. Stromal secreted protein acidic and rich in cysteine expression: A potential target for improved prognosis in patients with pancreatic cancer. Co-author DOI 10.4251/wjgo.v17.i11.110704↗
  2. Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer. Co-author DOI 10.3349/ymj.2023.0399↗
  3. Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2022.08.009↗
  4. Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer. Co-author DOI 10.1159/000525294↗
  5. Laparoscopic radical distal pancreatosplenectomy with celiac axis excision following neoadjuvant chemotherapy for locally advanced pancreatic cancer. Co-author DOI 10.14701/ahbps.21-097↗
  6. Laparoscopic distal pancreatosplenectomy for left-sided pancreatic cancer in patients with radical subtotal gastrectomy for gastric cancer. Co-author DOI 10.14701/ahbps.22-016↗
  7. Should the Splenic Vein Be Preserved-Fate of Sinistral Portal Hypertension after Pancreatoduodenectomy with Vascular Re-Section for Pancreatic Cancer. Co-author DOI 10.3390/cancers14194853↗
  8. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.5009/gnl20301↗
  9. MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer. Co-author DOI 10.1007/s13402-021-00643-8↗
  10. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. Co-author DOI 10.1016/j.pan.2021.02.007↗
  11. Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. Co-author DOI 10.1177/0284185120917118↗
  12. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  13. Laparoscopic pancreaticoduodenectomy in pancreatic ductal adenocarcinoma. Co-author DOI 10.7602/jmis.2021.24.3.169↗
  14. Unexpected Para-aortic Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma: a Contraindication to Resection? Co-author DOI 10.1007/s11605-019-04483-8↗
  15. Oncologic impact of preoperative prognostic nutritional index change in resected pancreatic cancer following neoadjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2019.12.006↗
  16. Oncologic Impact of Local Recurrence in Resected Pancreatic Cancer and Topographic Preference in Local Recurrence Patterns According to Tumor Location. Last author DOI 10.1097/mpa.0000000000001679↗
  17. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.14837↗
  18. Feasibility and Safety of Laparoscopic Radical Distal Pancreatosplenectomy with Adrenalectomy in Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08670-9↗
  19. Laparoscopic repeated pancreatectomy for isolated local recurrence in remnant pancreas following laparoscopic radical pancreatectomy for pancreatic ductal aden… Co-author DOI 10.14701/ahbps.2020.24.4.542↗
  20. Neoadjuvant chemotherapy followed by total pancreatectomy with splenectomy and combined vascular resections after preoperative percutaneous transhepatic portal… Co-author DOI 10.14701/ahbps.2020.24.4.551↗
  21. A nomogram to preoperatively predict 1-year disease-specific survival in resected pancreatic cancer following neoadjuvant chemoradiation therapy. Co-author DOI 10.21147/j.issn.1000-9604.2020.01.12↗
  22. Yonsei Criteria, a Potential Linkage to Intratumoral Foxp3⁺/CD8⁺ Ratio for the Prediction of Oncologic Outcomes in Resected Left-Sided Pancreatic Cancer. Last author DOI 10.3349/ymj.2020.61.4.291↗
  23. Is Laparoscopic Pancreaticoduodenectomy Feasible for Pancreatic Ductal Adenocarcinoma? First author DOI 10.3390/cancers12113430↗
  24. Intraoperative Transfusion is Independently Associated with a Worse Prognosis in Resected Pancreatic Cancer-a Retrospective Cohort Analysis. Co-author DOI 10.3390/jcm9030689↗
  25. Repeated Pancreatectomy for Isolated Local Recurrence in the Remnant Pancreas Following Radical Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Pooled A… Co-author DOI 10.3390/jcm9123945↗
  26. Developing a preoperative serum metabolome-based recurrence-predicting nomogram for patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-55016-x↗
  27. Association of preoperative total lymphocyte count with prognosis in resected left-sided pancreatic cancer. Co-author DOI 10.1111/ans.15030↗
  28. Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity… Last author DOI 10.1177/1534735418816825↗
  29. Preoperative Metabolic Tumor Volume2.5 Associated with Early Systemic Metastasis in Resected Pancreatic Cancer: A Transcriptome-Wide Analysis. Co-author DOI 10.5009/gnl18242↗
  30. Different biological behaviors in left-sided pancreatic cancer according to Yonsei criteria: Proposal of a modified Yonsei criteria score. Last author DOI 10.1016/j.pan.2018.09.001↗
  31. Adverse Oncologic Impact of New-Onset Diabetes Mellitus on Recurrence in Resected Pancreatic Ductal Adenocarcinoma: A Comparison With Long-standing and Non-Dia… Last author DOI 10.1097/mpa.0000000000001099↗
  32. The Yonsei criteria as a clinically detectable parameter for excellent prognosis in resected left-sided pancreatic cancer: outcomes of a propensity score-match… Last author DOI 10.1007/s00464-017-5529-6↗
  33. Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer. Last author DOI 10.1371/journal.pone.0172606↗
  34. Yonsei criteria: a clinical reflection of stage I left-sided pancreatic cancer. Last author DOI 10.18632/oncotarget.22734↗
  35. Negative oncologic impact of poor postoperative pain control in left-sided pancreatic cancer. Last author DOI 10.3748/wjg.v23.i4.676↗
  36. A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer. Last author DOI 10.3892/ol.2017.6696↗
  37. Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer: the need for strict transfusion policy. Last author DOI 10.1002/jhbp.368↗
  38. Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer. Last author DOI 10.1097/md.0000000000002595↗
  39. Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancrea… Last author DOI 10.1097/md.0000000000003452↗
  40. Identification of an N staging system that predicts oncologic outcome in resected left-sided pancreatic cancer. Co-author DOI 10.1097/md.0000000000004035↗
  41. Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer. First author DOI 10.1371/journal.pone.0157196↗
  42. Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic c… Last author DOI 10.3892/ol.2016.5252↗
  43. The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement. Last author DOI 10.1097/md.0000000000001233↗
  44. Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles. Last author DOI 10.1097/md.0000000000002168↗
  45. Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (>median 3 years) oncologic outcomes. Co-author DOI 10.1007/s00464-014-3537-3↗
  46. Fatal liver injury complicated by percutaneous catheter drainage after distal pancreatosplenectomy in a patient with pancreatic cancer. Last author DOI 10.14701/kjhbps.2014.18.2.64↗
  47. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer. Co-author DOI 10.2967/jnumed.113.131847↗
  48. A five-year survivor without recurrence following robotic anterior radical antegrade modular pancreatosplenectomy for a well-selected left-sided pancreatic can… Co-author DOI 10.3349/ymj.2014.55.1.276↗
  49. Validation of group B borderline resectable pancreatic cancer: retrospective analysis. Co-author DOI 10.5009/gnl13264↗
  50. Proposal for splenectomy-omitting radical distal pancreatectomy in well-selected left-sided pancreatic cancer: multicenter survey study. Last author DOI 10.1007/s00534-012-0549-z↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chang Moo Kang · 55 shared papers, 2011–2025 · strength 6.03
  2. Ho Kyoung Hwang · 47 shared papers, 2012–2025 · strength 5.58
  3. Sung Hyun Kim · 10 shared papers, 2016–2022 · strength 1.52
  4. Sung Hwan Lee · 12 shared papers, 2014–2021 · strength 1.18
  5. Munseok Choi · 6 shared papers, 2020–2022 · strength 0.88
  6. Jeong Youp Park · 9 shared papers, 2012–2022 · strength 0.67
  7. Jae Uk Chong · 5 shared papers, 2017–2025 · strength 0.65
  8. Si Young Song · 11 shared papers, 2012–2022 · strength 0.60
  9. Seoung Yoon Rho · 5 shared papers, 2018–2021 · strength 0.60
  10. Seungmin Bang · 8 shared papers, 2013–2022 · strength 0.58
  11. Hye Yeon Yang · 2 shared papers, 2024–2025 · strength 0.56
  12. Ji Su Kim · 3 shared papers, 2020–2022 · strength 0.53
  13. Seung‐seob Kim · 3 shared papers, 2022 · strength 0.52
  14. Seung Soo Hong · 3 shared papers, 2020–2022 · strength 0.51
  15. Moon Jae Chung · 6 shared papers, 2013–2022 · strength 0.46
  16. Sung Hoon Choi · 6 shared papers, 2011–2020 · strength 0.38
  17. Hee Seung Lee · 3 shared papers, 2020–2022 · strength 0.35
  18. Seung Woo Park · 5 shared papers, 2013–2022 · strength 0.34
  19. Dong Sup Yoon · 3 shared papers, 2019–2020 · strength 0.32
  20. Mi‐Suk Park · 2 shared papers, 2021–2022 · strength 0.25
  21. Man Deuk Kim · 2 shared papers, 2020–2021 · strength 0.25
  22. Jung Hyun Jo · 2 shared papers, 2020–2022 · strength 0.23
  23. Jinsil Seong · 4 shared papers, 2013–2016 · strength 0.19
  24. Hoon Sang Chi · 4 shared papers, 2011–2014 · strength 0.19
  25. Kang Hee Lee · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.